Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jul 15 | 2026Novo’s Wegovy Pill Receives Approval in EU; Gubra Initiates FIH Study for Muscle-Sparing Asset; GSK Initiates Ph3 Efimosfermin Studies in MASH; Fractyl One Year Data; Ascletis Selects Another FDC in Obesity; Rani Topline Ph1 Data; BI H1 2026 UpdatesPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Jul 14 | 2026D&D and Pfizer Expand Research Agreement; Dexcom G7 15-Day Health Canada Clearance; Insulet Partners with CalmPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Jul 13 | 2026Zverev Sports MiniMed at Wimbledon; CSPC/AZ Milestone Payment; Madrigal Rezdiffra Patents; Novo AMAZE 3 Zenagamtide StudyPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Jul 10 | 2026Novo Initiates NLPR3i Obesity Study; Rani Partners with China-based Biotech Drug Delivery; Pfizer Gets New Head of Obesity Discovery; Novo Sponsors Athletes at WimbledonPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jul 09 | 2026Hengrui Ph2 Triple Agonist Study; MindRank Series B; Semaglutide on NEDL; New Foundayo DTC Ad; Endogenex ReCET Enrollment Complete; Ionis/AZ Miss Primary Endpoint in CARDIO-TTRansform; Dr. Reddy’s Halts SemaPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Jul 07 | 2026Vivani + Novo Partner for Sema Implant; Kailera Ph3 Oral Obesity and T2DM Data; TIXiMED Ph1b MAD Study; ESC 2026 Hot Line SessionsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jul 06 | 2026AZ/CSPC CVRM Deal; Amgen Initiates New Ph1 T2DM Study; Ascletis Files US INDs; Regeneron Posts New Ph2 Olatorepatide Study; Trinity CGM+ Results; Wegovy MASH MHRA Approval; Adocia/Sanofi M1Pram Agreement Expiration; ViCentra Hybrid Closed Loop Germany LaunchPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jul 02 | 2026Lilly Ph1b Elora + Tirzep Preliminary Data; Ribo and Madrigal First siRNA Development Milestone; UpDoc FDA ClearancePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jul 01 | 2026Medicare GLP-1 Bridge Program Initiates; Tandem’s t:slim Pump and Abbott’s FreeStyle Libre 3+ Launch in Select UK/EU Markets; Hengrui Posts Ph3 Oral Ribupatide Study in China; Terrestrial Bio Doses First Patient with Needle-Free Sema Patch Technology; Tufts Health Eliminates Coverage for Dexcom CGMsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 29 | 2026Insulet Appoints Chief R&D Officer; FDA to Review Sandoz Generic Tirzepatide; Kailera Appoints Chief Affairs Officer; Resalis Doses First Patient in Ph1b Obesity StudyPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jun 26 | 2026June CHMP Meeting Highlights; New Enicepatide China-Based Ph3 Obesity Study; Cirius Initiates Ph2 Dosing in T1DM StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 26 | 2026Novo AMAZE 7 and 13 Zenagamtide Studies; New Ph2 UBT251 Study; Vivani Ph1 Sema Implant Study; TWL Virtual Tirzepatide Assessment; Anodyne $12.6M Series APurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jun 24 | 2026Viking Ph1 DACRA Study; Lilly Collaborates with Oura; Pivot Patch Pump US Launch; Wave Initiates Ph2a MAD INLIGHT Study; Wegovy FlexTouch Label Update; Tryngolza sHTG US ApprovalPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jun 24 | 2026ADA 2026 Winners/Not Winners Analysis: Who Came Out on Top… and Who Didn’t?Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i, Topics Jun 23 | 2026AZ Initiates Elecoglipron T2DM Pivotal Program; BI Ph2 Triple Agonist Obesity Study; Instinct + MiniMed Go and 780G EU Launch; CORXEL Ph2 Topline Oral GLP-1RA Data; Galectin to Advance Belapectin for MASHPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other, Topics Jun 22 | 2026Sanofi Appoints New EVP; CVS Expands GLP-1RA Support; COUR Closes $50M Series B; June CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 18 | 2026Denali Sells PRV For $195M; New China-Based UBT251 Obesity StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jun 17 | 2026Structure Initiates Pivotal Aleniglipron Studies; MiniMed Flex US Launch; FiberSense CGM CE Mark; FDA Compounding Warning LettersPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jun 16 | 2026New Mounjaro DTC TV Ad; Health Canada Approves Zepbound for OSA; BioAge Doses First Patient in Ph2 QUELL-CV StudyPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
